Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 14, 2016

View Archived Issues

Aurigene announces the exercise of Curis' option for CA-327

WK-0202 shows protective effects against Adriamycin-induced cardiotoxicity

Daiichi Sankyo and Dana-Farber Cancer Institute enter preclinical research collaboration

Ablynx discloses second extension of collaboration with Merck & Co. subsidiary

Transgene enters collaboration with Merck KGaA and Pfizer

First-line ribociclib plus letrozole highly effective in phase III breast cancer trial

Immunovaccine reports results from phase I trial of DPX-RSV

ContraVir reports interim data from phase IIa trial of CMX-157 in HBV

Aptose receives response from FDA regarding clinical hold for phase Ib trial of APTO-253

NIH grants support to Recombinetics' development of swine models of Alzheimer's and NF2

TG Therapeutics files amended protocol with FDA for GENUINE phase III trial

Regeneron and Ocular Therapeutix to develop sustained-release aflibercept for ophthalmic indications

Shenyang Sunshine Pharmaceutical patents PHD2 inhibitors

Sichuan Kelun Pharmaceutical Research discloses anticancer agents

SIWA-318 inhibits tumor metastasis in breast cancer mouse model

ZMapp beneficial but not superior to standard care in PREVAIL II Ebola virus disease trial

McGill University and Florida Institute of Technology describe OXER1 antagonists

Human Stem Cells Institute licenses Neovasculgen to ArtGen for development in the U.S. and Canada

Vertex Pharmaceuticals develops PAR2 antagonists

Anvyl presents deuterated etifoxine analogs

Sunovion submits NDA for SUN-101/Eflow

Novel mutation in GRK1 gene may cause Oguchi disease

Limited activity seen with single-agent buparlisib treatment in CNS lymphoma trial

Aslan enters collaboration with Nanyang Technological University to develop modybodies

Oncogenex Pharmaceuticals reports results for phase III ENSPIRIT trial of custirsen

Novel KERA mutations associated with cornea plana

AC-0010 shows promising anticancer activity in NSCLC patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...